RecruitingRecurrent UTIsRecurrent Urinary Tract InfectionsRecurrent Urinary Tract Infections in Women
A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections
Eligible age
55–85 yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A randomized, double-blind, placebo-controlled, 12-month study to determine the effectiveness of D-mannose (2g daily) supplementation in rUTI (recurrent urinary tract infection) prevention in post-menopausal women.
Sponsor: University of Texas Southwestern Medical Center
You may qualify if…
- ✓ Female, post-menopausal, age ≥ 55 years old
- ✓ Diagnosis of recurrent UTI, defined as ≥ 3 symptomatic culture-proven UTI episodes in 12 months or ≥ 2 in 6 months.
- ✓ Currently free from a UTI determined based on absence of symptoms as determined by the UTI symptom assessment questionnaire79 and negative urine culture (\<103 colony forming units per ml of urine).
- ✓ Able to attend all follow-up appointments for the study.
- ✓ A negative upper and lower urinary tract evaluation, including pelvic examination for pelvic organ prolapse (less than stage 2), measurement of post-void residual (less than 50 ml), and imaging (renal ultrasound and standing voiding cystourethrogram) to exclude kidney stone, hydronephrosis, reflux, or urethral diverticulum.
You may not qualify if…
- ✕ Current use of D-mannose. Patients willing to stop taking D-mannose will be offered to join the trial after a 4-week wash-out period.
- ✕ Complicated UTIs, including need for catheter drainage or intermittent catheterization, neurogenic bladder, bladder augmentation, or urinary diversion.
- ✕ Ongoing supplement use (Box 1). Patients willing to stop taking the listed supplements will be offered to join the trial after a 4-week wash-out period.
- ✕ Evidence of upper tract infection (pyelonephritis), including temperature higher than 38°C, flank/lumbar pain or tenderness
- ✕ Diagnosis of interstitial cystitis or overactive bladder syndrome
- ✕ Prophylactic antibiotics started in the last 3 months and unwilling to discontinue, or intention to start in the next 12 months
- ✕ Use of Uromune or other vaccine approaches to reduce rUTI
- ✕ Participation in a research study involving an investigational product in the past 12 weeks
Where it's recruiting
Texas
Dallas
Source: ClinicalTrials.gov · NCT06940622 · last updated 2025-09-22